Loading
Every cancer, every way to detect and treat it, every drug, target, trial, and term. One page each, in plain English first.
State of the art, standard of care, history, pipeline.
Every cancer type on one layered map: organ system to cancer to subtype, with a cancer under more than one node where it belongs to both. Badges count trials, products, approvals or ideas.
The fronts of the war: imaging to cell therapy.
Every way we see, measure, or attack a tumour.
The molecules drugs and tracers aim at.
PD-L1 CPS, HER2 IHC 3+, MSI-high: each readout under its gene, with the thresholds approvals use and the tests that measure it.
Approved and pipeline products, with rotating molecules.
Signalling circuits, drawn and explained.
One word, two biologies: immune checkpoints on the synapse and cell-cycle gates on the ring, each member with its partner, expression, drugs and approvals.
Why a virus kills a cancer cell and not its neighbour, every approved product with what its trial really showed, and the failures.
Everything about a target on one page: biology, prevalence, hotspots, products by phase, trials, resistance, assays, models, open questions, external ids.
Which pathway nodes have a drug, at what phase, and which druggable nodes have none.
BostonGene, Tempus, Foundation Medicine, Caris, Guardant and the rest side by side: tissue or blood, panel or exome, what the report returns, and regulatory status where certain.
Foundation models and the datasets they train on, with parameters, weights, licence and benchmarks.
The scanners, accelerators, robots and ablation devices hospitals use against cancer: what each does, its advantages and limits, who makes it, and which centres run the rare ones.
Unresolved questions per target and technology: why open, what would answer them, who acts.
Cell lines with Cellosaurus and DepMap ids, PDX banks, mouse models and organoids per cancer and target.
Named regimens with doses, days, cycles, emetogenicity and G-CSF need; calendar strip per regimen.
Per cancer, the standard of care by line and biomarker subgroup, with sequence and caution pairings.
TNM, FIGO, Lugano, BCLC, R-ISS and interactive IPI, IMDC, CLL-IPI, Child-Pugh, Khorana scorers.
What the next twelve months look like for a cancer at a stage, phase by phase, with the decision points.
Organ schematics with subsites and node stations, and where each cancer spreads.
Every product with a 3D structure, filterable by modality, payload, target and status.
How cancer works, drawn stage by stage, with the drugs that act on each mechanism.
How common each target is in each cancer.
Landmark and current trials.
What works together, and what does not.
History to horizon for each technology family.
What each technology needs to exist, drawn in layers from foundations to end products: what CAR-T cannot run without, and what stops if one step fails.
The constraints slowing the whole war on cancer, and the ideas that could break each one.
Hypotheses and fixes, each with a proposed test.
Terms with TL;DRs and Wikipedia links.
The open databases the field runs on.